Maryland facility gives Kite room to grow in CAR-T

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Lamontak590623)
(Image: Getty/Lamontak590623)

Related tags: Kite, Gilead, CAR-T, Yescarta

Kite adds a facility in Maryland to expand manufacturing capabilities of its CAR-T therapies, including Yescarta.

Kite, a Gilead company, focuses on the development of cancer immunotherapies​, specifically chimeric antigen receptor (CAR)-T therapies and T cell receptor engineered cell therapies.

Its new 20-acre site, based in Frederick County, Maryland, will expand Kite’s capacity to produce its cell therapies. According to Kite, CAR-T therapies require many complex and carefully controlled, multi-step processes.

A spokesperson for Kite told us, “Cell therapy manufacturing is a unique and highly scientific process. Unlike traditional biomanufacturing, current CAR-T therapies require a complex and carefully controlled, multi-step process that can be difficult to optimize.”

“Expanding and investing in our manufacturing capabilities is essential to ensuring we are able to meet the needs of CAR-T patients,”​ the spokesperson continued.

Currently, Kite has one commercially available CAR-T cancer therapy​, Yescarta, and is investigating T cell receptor cell therapies for solid tumors.

Tim Moore, EVP of technical operations at Kite, said in a statement that the company can build and design the Maryland facility to be tailored to its own proprietary innovative processes for CAR-T manufacture, as well as to meet the future needs for cell therapies as it continues to innovate its procedures.  

Kite anticipates commercial production to begin at the site by late 2021.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Follow us


View more